azenosertib
ZN-c3 · ZN-c3-002 · MUIR Small Molecule Target: WEE1
Zentalis Pharmaceuticals
Most recent annual filing: 2026-03-26
- Azenosertib corporate updateby year-end 2026Azenosertib corporate update, by year-end 2026, notable
- Azenosertib China decisionDec 2026Azenosertib China decision, Dec 2026, material
- Azenosertib topline1H 2027Azenosertib topline, 1H 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Discontinued (1)
- azenosertib — Uterine Serous Carcinoma · We do not plan further development of azenosertib in USC.
Biotech Distilled coverage (1)
- 2026-08-21 Zentalis Pharmaceuticals (ZNTL) - Scientific Deep Dive for Azenosertib and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.